#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	coref	6-7
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	ana	3-11

#Text=Proteases are associated with many signaling biological pathways , and it is has been proven that the number of diseases like cancer , HIV , infectious diseases , and diabetes are treated by inhibiting proteases .
3-1	17-26	Proteases	substance	new	coref	3-35
3-2	27-30	are	_	_	_	_
3-3	31-41	associated	_	_	_	_
3-4	42-46	with	_	_	_	_
3-5	47-51	many	abstract[4]	new[4]	_	_
3-6	52-61	signaling	abstract[4]	new[4]	_	_
3-7	62-72	biological	abstract[4]	new[4]	_	_
3-8	73-81	pathways	abstract[4]	new[4]	_	_
3-9	82-83	,	_	_	_	_
3-10	84-87	and	_	_	_	_
3-11	88-90	it	abstract	giv	_	_
3-12	91-93	is	_	_	_	_
3-13	94-97	has	_	_	_	_
3-14	98-102	been	_	_	_	_
3-15	103-109	proven	_	_	_	_
3-16	110-114	that	_	_	_	_
3-17	115-118	the	abstract[6]	new[6]	_	_
3-18	119-125	number	abstract[6]	new[6]	_	_
3-19	126-128	of	abstract[6]	new[6]	_	_
3-20	129-137	diseases	abstract[6]|abstract[7]	new[6]|new[7]	coref	6-13[31_7]
3-21	138-142	like	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-22	143-149	cancer	abstract[6]|abstract[7]|abstract	new[6]|new[7]|new	_	_
3-23	150-151	,	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-24	152-155	HIV	abstract[6]|abstract[7]|abstract	new[6]|new[7]|new	_	_
3-25	156-157	,	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-26	158-168	infectious	abstract[6]|abstract[7]|abstract[10]	new[6]|new[7]|new[10]	_	_
3-27	169-177	diseases	abstract[6]|abstract[7]|abstract[10]	new[6]|new[7]|new[10]	_	_
3-28	178-179	,	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-29	180-183	and	abstract[6]|abstract[7]	new[6]|new[7]	_	_
3-30	184-192	diabetes	abstract[6]|abstract[7]|abstract	new[6]|new[7]|new	coref	12-23
3-31	193-196	are	_	_	_	_
3-32	197-204	treated	_	_	_	_
3-33	205-207	by	_	_	_	_
3-34	208-218	inhibiting	_	_	_	_
3-35	219-228	proteases	substance	giv	coref	4-8[15_0]
3-36	229-230	.	_	_	_	_

#Text=Pharmaceutical companies develop commercial drugs to inhibit aspartyl proteases , serine proteases , and cysteine proteases .
4-1	231-245	Pharmaceutical	organization[13]	new[13]	_	_
4-2	246-255	companies	organization[13]	new[13]	_	_
4-3	256-263	develop	_	_	_	_
4-4	264-274	commercial	substance[14]	new[14]	coref	8-24[50_14]
4-5	275-280	drugs	substance[14]	new[14]	_	_
4-6	281-283	to	_	_	_	_
4-7	284-291	inhibit	_	_	_	_
4-8	292-300	aspartyl	substance[15]	giv[15]	_	_
4-9	301-310	proteases	substance[15]	giv[15]	_	_
4-10	311-312	,	substance[15]	giv[15]	_	_
4-11	313-319	serine	substance[15]|animal	giv[15]|new	coref	5-6
4-12	320-329	proteases	substance[15]	giv[15]	_	_
4-13	330-331	,	substance[15]	giv[15]	_	_
4-14	332-335	and	substance[15]	giv[15]	_	_
4-15	336-344	cysteine	substance[15]|abstract	giv[15]|new	_	_
4-16	345-354	proteases	substance[15]	giv[15]	_	_
4-17	355-356	.	_	_	_	_

#Text=Among several protease inhibitors , serine protease inhibitors received significant interest in various applications focused mainly in therapeutics .
5-1	357-362	Among	_	_	_	_
5-2	363-370	several	abstract[19]	new[19]	_	_
5-3	371-379	protease	abstract|abstract[19]	new|new[19]	coref	5-7
5-4	380-390	inhibitors	abstract[19]	new[19]	_	_
5-5	391-392	,	_	_	_	_
5-6	393-399	serine	animal|abstract[22]	giv|new[22]	coref|coref|coref|coref	6-1|6-1[28_22]|6-1|6-1[28_22]
5-7	400-408	protease	abstract|abstract[22]	giv|new[22]	coref	6-2
5-8	409-419	inhibitors	abstract[22]	new[22]	_	_
5-9	420-428	received	_	_	_	_
5-10	429-440	significant	abstract[23]	new[23]	_	_
5-11	441-449	interest	abstract[23]	new[23]	_	_
5-12	450-452	in	_	_	_	_
5-13	453-460	various	abstract[24]	new[24]	_	_
5-14	461-473	applications	abstract[24]	new[24]	_	_
5-15	474-481	focused	_	_	_	_
5-16	482-488	mainly	_	_	_	_
5-17	489-491	in	_	_	_	_
5-18	492-504	therapeutics	abstract	new	coref	7-23[44_0]
5-19	505-506	.	_	_	_	_

#Text=Serine protease inhibitors shown in Table 1 , are used in treating diseases like immune-related disorders , inflammatory , respiratory , AIDS , neurodegenerative , and metabolic disorders .
6-1	507-513	Serine	animal|abstract[28]	giv|giv[28]	coref|coref|coref|coref	14-9|20-12[182_28]|14-9|20-12[182_28]
6-2	514-522	protease	abstract|abstract[28]	giv|giv[28]	coref	9-9[55_0]
6-3	523-533	inhibitors	abstract[28]	giv[28]	_	_
6-4	534-539	shown	_	_	_	_
6-5	540-542	in	_	_	_	_
6-6	543-548	Table	object	new	coref	8-13[47_0]
6-7	549-550	1	quantity	giv	_	_
6-8	551-552	,	_	_	_	_
6-9	553-556	are	_	_	_	_
6-10	557-561	used	_	_	_	_
6-11	562-564	in	_	_	_	_
6-12	565-573	treating	_	_	_	_
6-13	574-582	diseases	abstract[31]	giv[31]	coref	13-31[101_31]
6-14	583-587	like	abstract[31]	giv[31]	_	_
6-15	588-602	immune-related	abstract[31]|abstract[32]	giv[31]|new[32]	_	_
6-16	603-612	disorders	abstract[31]|abstract[32]	giv[31]|new[32]	_	_
6-17	613-614	,	abstract[31]	giv[31]	_	_
6-18	615-627	inflammatory	abstract[31]	giv[31]	_	_
6-19	628-629	,	abstract[31]	giv[31]	_	_
6-20	630-641	respiratory	abstract[31]	giv[31]	_	_
6-21	642-643	,	abstract[31]	giv[31]	_	_
6-22	644-648	AIDS	abstract[31]|abstract	giv[31]|new	_	_
6-23	649-650	,	abstract[31]	giv[31]	_	_
6-24	651-668	neurodegenerative	abstract[31]|abstract	giv[31]|new	_	_
6-25	669-670	,	abstract[31]	giv[31]	_	_
6-26	671-674	and	abstract[31]	giv[31]	_	_
6-27	675-684	metabolic	abstract[31]|abstract|abstract[36]	giv[31]|new|new[36]	coref|coref	8-27[51_36]|8-27[51_36]
6-28	685-694	disorders	abstract[31]|abstract[36]	giv[31]|new[36]	_	_
6-29	695-696	.	_	_	_	_

#Text=Features like therapeutic potential , good binding affinity , low toxicity , and quickly cleavable by proteolytic enzymes , make cyclic peptides potential future therapeutics .
7-1	697-705	Features	abstract[37]	new[37]	_	_
7-2	706-710	like	abstract[37]	new[37]	_	_
7-3	711-722	therapeutic	abstract[37]|abstract[39]	new[37]|new[39]	_	_
7-4	723-732	potential	abstract[37]|abstract[39]	new[37]|new[39]	_	_
7-5	733-734	,	abstract[37]|abstract[39]	new[37]|new[39]	_	_
7-6	735-739	good	abstract[37]|abstract[39]	new[37]|new[39]	_	_
7-7	740-747	binding	abstract[37]|object|abstract[39]	new[37]|new|new[39]	coref	22-10
7-8	748-756	affinity	abstract[37]|abstract[39]	new[37]|new[39]	_	_
7-9	757-758	,	abstract[37]	new[37]	_	_
7-10	759-762	low	abstract[37]|abstract[40]	new[37]|new[40]	coref	18-28[149_40]
7-11	763-771	toxicity	abstract[37]|abstract[40]	new[37]|new[40]	_	_
7-12	772-773	,	abstract[37]	new[37]	_	_
7-13	774-777	and	abstract[37]	new[37]	_	_
7-14	778-785	quickly	abstract[37]|abstract[41]	new[37]|new[41]	_	_
7-15	786-795	cleavable	abstract[37]|abstract[41]	new[37]|new[41]	_	_
7-16	796-798	by	abstract[37]|abstract[41]	new[37]|new[41]	_	_
7-17	799-810	proteolytic	abstract[37]|abstract[41]|object[42]	new[37]|new[41]|new[42]	_	_
7-18	811-818	enzymes	abstract[37]|abstract[41]|object[42]	new[37]|new[41]|new[42]	_	_
7-19	819-820	,	_	_	_	_
7-20	821-825	make	_	_	_	_
7-21	826-832	cyclic	abstract[43]	new[43]	coref	8-1[45_43]
7-22	833-841	peptides	abstract[43]	new[43]	_	_
7-23	842-851	potential	abstract[43]|abstract[44]	new[43]|giv[44]	coref	18-56[0_44]
7-24	852-858	future	abstract[43]|abstract[44]	new[43]|giv[44]	_	_
7-25	859-871	therapeutics	abstract[43]|abstract[44]	new[43]|giv[44]	_	_
7-26	872-873	.	_	_	_	_

#Text=Most of the cyclic peptides approved by the FDA ( shown in Table 2 ) are used in bacterial and fungal infections , oncology drugs , gastrointestinal disorders , and anemia .
8-1	874-878	Most	abstract[45]	giv[45]	coref	9-3[53_45]
8-2	879-881	of	abstract[45]	giv[45]	_	_
8-3	882-885	the	abstract[45]	giv[45]	_	_
8-4	886-892	cyclic	abstract[45]	giv[45]	_	_
8-5	893-901	peptides	abstract[45]	giv[45]	_	_
8-6	902-910	approved	_	_	_	_
8-7	911-913	by	_	_	_	_
8-8	914-917	the	organization[46]	new[46]	_	_
8-9	918-921	FDA	organization[46]	new[46]	_	_
8-10	922-923	(	_	_	_	_
8-11	924-929	shown	_	_	_	_
8-12	930-932	in	_	_	_	_
8-13	933-938	Table	object[47]	giv[47]	_	_
8-14	939-940	2	object[47]	giv[47]	_	_
8-15	941-942	)	_	_	_	_
8-16	943-946	are	_	_	_	_
8-17	947-951	used	_	_	_	_
8-18	952-954	in	_	_	_	_
8-19	955-964	bacterial	substance	new	_	_
8-20	965-968	and	_	_	_	_
8-21	969-975	fungal	object[49]	new[49]	_	_
8-22	976-986	infections	object[49]	new[49]	_	_
8-23	987-988	,	_	_	_	_
8-24	989-997	oncology	substance[50]	giv[50]	_	_
8-25	998-1003	drugs	substance[50]	giv[50]	_	_
8-26	1004-1005	,	_	_	_	_
8-27	1006-1022	gastrointestinal	abstract[51]	giv[51]	_	_
8-28	1023-1032	disorders	abstract[51]	giv[51]	_	_
8-29	1033-1034	,	_	_	_	_
8-30	1035-1038	and	_	_	_	_
8-31	1039-1045	anemia	abstract	new	_	_
8-32	1046-1047	.	_	_	_	_

#Text=Recently , cyclic peptides were proven to inhibit HIV-1 protease ( aspartyl proteases ) and elastase , shedding light onto the use of cyclic peptides as protease inhibitors .
9-1	1048-1056	Recently	_	_	_	_
9-2	1057-1058	,	_	_	_	_
9-3	1059-1065	cyclic	abstract[53]	giv[53]	coref	9-24[59_53]
9-4	1066-1074	peptides	abstract[53]	giv[53]	_	_
9-5	1075-1079	were	_	_	_	_
9-6	1080-1086	proven	_	_	_	_
9-7	1087-1089	to	_	_	_	_
9-8	1090-1097	inhibit	_	_	_	_
9-9	1098-1103	HIV-1	abstract|abstract[55]	new|giv[55]	appos|appos	9-12[56_55]|9-12[56_55]
9-10	1104-1112	protease	abstract[55]	giv[55]	_	_
9-11	1113-1114	(	_	_	_	_
9-12	1115-1123	aspartyl	abstract[56]	giv[56]	coref	9-27[0_56]
9-13	1124-1133	proteases	abstract[56]	giv[56]	_	_
9-14	1134-1135	)	_	_	_	_
9-15	1136-1139	and	_	_	_	_
9-16	1140-1148	elastase	_	_	_	_
9-17	1149-1150	,	_	_	_	_
9-18	1151-1159	shedding	_	_	_	_
9-19	1160-1165	light	abstract	new	_	_
9-20	1166-1170	onto	_	_	_	_
9-21	1171-1174	the	abstract[58]	new[58]	_	_
9-22	1175-1178	use	abstract[58]	new[58]	_	_
9-23	1179-1181	of	abstract[58]	new[58]	_	_
9-24	1182-1188	cyclic	abstract[58]|abstract[59]	new[58]|giv[59]	coref	10-9[65_59]
9-25	1189-1197	peptides	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
9-26	1198-1200	as	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
9-27	1201-1209	protease	abstract[58]|abstract[59]|abstract	new[58]|giv[59]|giv	coref	12-14
9-28	1210-1220	inhibitors	abstract[58]|abstract[59]	new[58]|giv[59]	_	_
9-29	1221-1222	.	_	_	_	_

#Text=Phage display technology , Incretin-based cyclic peptide , cyclic peptides from mRNA display , and split-pool synthesis are some of the tools used to develop cyclic peptide compounds .
10-1	1223-1228	Phage	place|abstract[63]	new|new[63]	_	_
10-2	1229-1236	display	object|abstract[63]	new|new[63]	coref	10-12[67_0]
10-3	1237-1247	technology	abstract[63]	new[63]	_	_
10-4	1248-1249	,	_	_	_	_
10-5	1250-1264	Incretin-based	object[64]	new[64]	coref	10-27[0_64]
10-6	1265-1271	cyclic	object[64]	new[64]	_	_
10-7	1272-1279	peptide	object[64]	new[64]	_	_
10-8	1280-1281	,	_	_	_	_
10-9	1282-1288	cyclic	abstract[65]	giv[65]	coref	12-4[83_65]
10-10	1289-1297	peptides	abstract[65]	giv[65]	_	_
10-11	1298-1302	from	abstract[65]	giv[65]	_	_
10-12	1303-1307	mRNA	abstract[65]|event|object[67]	giv[65]|new|giv[67]	_	_
10-13	1308-1315	display	abstract[65]|object[67]	giv[65]|giv[67]	_	_
10-14	1316-1317	,	_	_	_	_
10-15	1318-1321	and	_	_	_	_
10-16	1322-1332	split-pool	abstract[68]	new[68]	_	_
10-17	1333-1342	synthesis	abstract[68]	new[68]	_	_
10-18	1343-1346	are	_	_	_	_
10-19	1347-1351	some	_	_	_	_
10-20	1352-1354	of	_	_	_	_
10-21	1355-1358	the	abstract[69]	new[69]	_	_
10-22	1359-1364	tools	abstract[69]	new[69]	_	_
10-23	1365-1369	used	_	_	_	_
10-24	1370-1372	to	_	_	_	_
10-25	1373-1380	develop	_	_	_	_
10-26	1381-1387	cyclic	abstract[71]	new[71]	_	_
10-27	1388-1395	peptide	object|abstract[71]	giv|new[71]	coref	11-28
10-28	1396-1405	compounds	abstract[71]	new[71]	_	_
10-29	1406-1407	.	_	_	_	_

#Text=Recently computer-aided drug design technologies like molecular docking simulations are applied to identify , design rationally ( called as de novo developed ) , and develop cyclic peptide ligand as leads to therapeutic drug targets of interest .
11-1	1408-1416	Recently	_	_	_	_
11-2	1417-1431	computer-aided	abstract[74]	new[74]	_	_
11-3	1432-1436	drug	substance|abstract[74]	new|new[74]	coref	11-34
11-4	1437-1443	design	abstract|abstract[74]	new|new[74]	coref	11-15
11-5	1444-1456	technologies	abstract[74]	new[74]	_	_
11-6	1457-1461	like	abstract[74]	new[74]	_	_
11-7	1462-1471	molecular	abstract[74]|abstract[76]	new[74]|new[76]	coref	21-4[189_76]
11-8	1472-1479	docking	abstract[74]|place|abstract[76]	new[74]|new|new[76]	coref	21-5
11-9	1480-1491	simulations	abstract[74]|abstract[76]	new[74]|new[76]	_	_
11-10	1492-1495	are	_	_	_	_
11-11	1496-1503	applied	_	_	_	_
11-12	1504-1506	to	_	_	_	_
11-13	1507-1515	identify	_	_	_	_
11-14	1516-1517	,	_	_	_	_
11-15	1518-1524	design	abstract	giv	_	_
11-16	1525-1535	rationally	_	_	_	_
11-17	1536-1537	(	_	_	_	_
11-18	1538-1544	called	_	_	_	_
11-19	1545-1547	as	_	_	_	_
11-20	1548-1550	de	_	_	_	_
11-21	1551-1555	novo	_	_	_	_
11-22	1556-1565	developed	_	_	_	_
11-23	1566-1567	)	_	_	_	_
11-24	1568-1569	,	_	_	_	_
11-25	1570-1573	and	_	_	_	_
11-26	1574-1581	develop	_	_	_	_
11-27	1582-1588	cyclic	abstract[79]	new[79]	_	_
11-28	1589-1596	peptide	object|abstract[79]	giv|new[79]	coref	16-9
11-29	1597-1603	ligand	abstract[79]	new[79]	_	_
11-30	1604-1606	as	_	_	_	_
11-31	1607-1612	leads	_	_	_	_
11-32	1613-1615	to	_	_	_	_
11-33	1616-1627	therapeutic	abstract[81]	new[81]	_	_
11-34	1628-1632	drug	substance|abstract[81]	giv|new[81]	coref	14-16
11-35	1633-1640	targets	abstract[81]	new[81]	_	_
11-36	1641-1643	of	abstract[81]	new[81]	_	_
11-37	1644-1652	interest	abstract[81]	new[81]	_	_
11-38	1653-1654	.	_	_	_	_

#Text=Till today , cyclic peptides as therapeutics in regulating glucose metabolism by inhibiting proteases have not been reported for the treatment of diabetes mellitus .
12-1	1655-1659	Till	_	_	_	_
12-2	1660-1665	today	time	new	_	_
12-3	1666-1667	,	_	_	_	_
12-4	1668-1674	cyclic	abstract[83]	giv[83]	coref	18-2[143_83]
12-5	1675-1683	peptides	abstract[83]	giv[83]	_	_
12-6	1684-1686	as	abstract[83]	giv[83]	_	_
12-7	1687-1699	therapeutics	abstract[83]	giv[83]	_	_
12-8	1700-1702	in	_	_	_	_
12-9	1703-1713	regulating	_	_	_	_
12-10	1714-1721	glucose	substance|abstract[85]	new|new[85]	coref|coref|coref|coref	14-21|14-20[111_85]|14-21|14-20[111_85]
12-11	1722-1732	metabolism	abstract[85]	new[85]	_	_
12-12	1733-1735	by	_	_	_	_
12-13	1736-1746	inhibiting	_	_	_	_
12-14	1747-1756	proteases	substance	giv	coref	18-9[144_0]
12-15	1757-1761	have	_	_	_	_
12-16	1762-1765	not	_	_	_	_
12-17	1766-1770	been	_	_	_	_
12-18	1771-1779	reported	_	_	_	_
12-19	1780-1783	for	_	_	_	_
12-20	1784-1787	the	abstract[87]	new[87]	_	_
12-21	1788-1797	treatment	abstract[87]	new[87]	_	_
12-22	1798-1800	of	abstract[87]	new[87]	_	_
12-23	1801-1809	diabetes	abstract[87]|abstract|abstract[89]	new[87]|giv|new[89]	coref|coref|coref|coref	13-10|13-10[93_89]|13-10|13-10[93_89]
12-24	1810-1818	mellitus	abstract[87]|abstract[89]	new[87]|new[89]	_	_
12-25	1819-1820	.	_	_	_	_

#Text=In Mexico , approximately 11.5 million people live with diabetes mellitus ( DM ) , which is the main leading cause of acquired blindness , non-traumatic lower-limb amputations , and chronic kidney failure diseases .
13-1	1821-1823	In	_	_	_	_
13-2	1824-1830	Mexico	place	new	_	_
13-3	1831-1832	,	_	_	_	_
13-4	1833-1846	approximately	quantity[91]	new[91]	_	_
13-5	1847-1851	11.5	quantity[91]	new[91]	_	_
13-6	1852-1859	million	quantity[91]	new[91]	_	_
13-7	1860-1866	people	quantity[91]	new[91]	_	_
13-8	1867-1871	live	_	_	_	_
13-9	1872-1876	with	_	_	_	_
13-10	1877-1885	diabetes	abstract|abstract[93]	giv|giv[93]	coref|coref|coref|coref	14-25|14-25[113_93]|14-25|14-25[113_93]
13-11	1886-1894	mellitus	abstract[93]	giv[93]	_	_
13-12	1895-1896	(	_	_	_	_
13-13	1897-1899	DM	abstract	new	_	_
13-14	1900-1901	)	_	_	_	_
13-15	1902-1903	,	_	_	_	_
13-16	1904-1909	which	_	_	_	_
13-17	1910-1912	is	_	_	_	_
13-18	1913-1916	the	abstract[95]	new[95]	_	_
13-19	1917-1921	main	abstract[95]	new[95]	_	_
13-20	1922-1929	leading	abstract[95]	new[95]	_	_
13-21	1930-1935	cause	abstract[95]	new[95]	_	_
13-22	1936-1938	of	abstract[95]	new[95]	_	_
13-23	1939-1947	acquired	abstract[95]|abstract[96]	new[95]|new[96]	_	_
13-24	1948-1957	blindness	abstract[95]|abstract[96]	new[95]|new[96]	_	_
13-25	1958-1959	,	abstract[95]	new[95]	_	_
13-26	1960-1973	non-traumatic	abstract[95]|object[98]	new[95]|new[98]	_	_
13-27	1974-1984	lower-limb	abstract[95]|event|object[98]	new[95]|new|new[98]	_	_
13-28	1985-1996	amputations	abstract[95]|object[98]	new[95]|new[98]	_	_
13-29	1997-1998	,	abstract[95]	new[95]	_	_
13-30	1999-2002	and	abstract[95]	new[95]	_	_
13-31	2003-2010	chronic	abstract[95]|abstract[101]	new[95]|giv[101]	_	_
13-32	2011-2017	kidney	abstract[95]|object|abstract[101]	new[95]|new|giv[101]	_	_
13-33	2018-2025	failure	abstract[95]|abstract|abstract[101]	new[95]|new|giv[101]	_	_
13-34	2026-2034	diseases	abstract[95]|abstract[101]	new[95]|giv[101]	_	_
13-35	2035-2036	.	_	_	_	_

#Text=Human dipeptidyl peptidase-4 ( DPP4 ) is a serine protease , well known FDA-approved therapeutic drug target for regulating blood glucose metabolism and treating diabetes mellitus .
14-1	2037-2042	Human	object[103]	new[103]	coref	14-8[106_103]
14-2	2043-2053	dipeptidyl	abstract|object[103]	new|new[103]	coref	15-19
14-3	2054-2065	peptidase-4	object[103]	new[103]	_	_
14-4	2066-2067	(	_	_	_	_
14-5	2068-2072	DPP4	object	new	coref	15-22
14-6	2073-2074	)	_	_	_	_
14-7	2075-2077	is	_	_	_	_
14-8	2078-2079	a	object[106]	giv[106]	coref	15-18[121_106]
14-9	2080-2086	serine	animal|object[106]	giv|giv[106]	coref	17-7
14-10	2087-2095	protease	object[106]	giv[106]	_	_
14-11	2096-2097	,	object[106]	giv[106]	_	_
14-12	2098-2102	well	object[106]	giv[106]	_	_
14-13	2103-2108	known	object[106]	giv[106]	_	_
14-14	2109-2121	FDA-approved	object[106]|abstract[108]	giv[106]|new[108]	_	_
14-15	2122-2133	therapeutic	object[106]|abstract[108]	giv[106]|new[108]	_	_
14-16	2134-2138	drug	object[106]|substance|abstract[108]	giv[106]|giv|new[108]	_	_
14-17	2139-2145	target	object[106]|abstract[108]	giv[106]|new[108]	_	_
14-18	2146-2149	for	_	_	_	_
14-19	2150-2160	regulating	_	_	_	_
14-20	2161-2166	blood	substance|abstract[111]	new|giv[111]	_	_
14-21	2167-2174	glucose	substance|abstract[111]	giv|giv[111]	coref	16-27
14-22	2175-2185	metabolism	abstract[111]	giv[111]	_	_
14-23	2186-2189	and	_	_	_	_
14-24	2190-2198	treating	_	_	_	_
14-25	2199-2207	diabetes	abstract|abstract[113]	giv|giv[113]	coref|coref|coref|coref	18-65|18-65[163_113]|18-65|18-65[163_113]
14-26	2208-2216	mellitus	abstract[113]	giv[113]	_	_
14-27	2217-2218	.	_	_	_	_

#Text=Sitagliptin , Vildagliptin , Anagliptin , Saxagliptin , and Alogliptin are the main clinically used chemicals for human dipeptidyl peptidase-4 ( DPP4 ) inhibition despite their side effects as pancreatitis , nausea , and anemia .
15-1	2219-2230	Sitagliptin	substance	new	_	_
15-2	2231-2232	,	_	_	_	_
15-3	2233-2245	Vildagliptin	substance	new	_	_
15-4	2246-2247	,	_	_	_	_
15-5	2248-2258	Anagliptin	substance	new	_	_
15-6	2259-2260	,	_	_	_	_
15-7	2261-2272	Saxagliptin	substance	new	_	_
15-8	2273-2274	,	_	_	_	_
15-9	2275-2278	and	_	_	_	_
15-10	2279-2289	Alogliptin	substance	new	coref	15-12[119_0]
15-11	2290-2293	are	_	_	_	_
15-12	2294-2297	the	substance[119]	giv[119]	coref	18-24[148_119]
15-13	2298-2302	main	substance[119]	giv[119]	_	_
15-14	2303-2313	clinically	substance[119]	giv[119]	_	_
15-15	2314-2318	used	substance[119]	giv[119]	_	_
15-16	2319-2328	chemicals	substance[119]	giv[119]	_	_
15-17	2329-2332	for	substance[119]	giv[119]	_	_
15-18	2333-2338	human	substance[119]|substance[121]	giv[119]|giv[121]	coref	17-6[141_121]
15-19	2339-2349	dipeptidyl	substance[119]|abstract|substance[121]	giv[119]|giv|giv[121]	coref	17-10
15-20	2350-2361	peptidase-4	substance[119]|substance[121]	giv[119]|giv[121]	_	_
15-21	2362-2363	(	substance[119]	giv[119]	_	_
15-22	2364-2368	DPP4	substance[119]|abstract	giv[119]|giv	coref	17-13
15-23	2369-2370	)	substance[119]	giv[119]	_	_
15-24	2371-2381	inhibition	substance[119]|abstract[123]	giv[119]|new[123]	ana	16-1[0_123]
15-25	2382-2389	despite	substance[119]|abstract[123]	giv[119]|new[123]	_	_
15-26	2390-2395	their	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-27	2396-2400	side	substance[119]|abstract[123]|abstract|abstract[125]	giv[119]|new[123]|new|new[125]	_	_
15-28	2401-2408	effects	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-29	2409-2411	as	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-30	2412-2424	pancreatitis	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-31	2425-2426	,	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-32	2427-2433	nausea	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-33	2434-2435	,	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-34	2436-2439	and	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-35	2440-2446	anemia	substance[119]|abstract[123]|abstract[125]	giv[119]|new[123]|new[125]	_	_
15-36	2447-2448	.	_	_	_	_

#Text=It is well known that incretin hormones glucagon-like peptide 1 ( GLP-1 ) and glucose-dependent insulinotropic polypeptide ( GIP ) are responsible for insulin release and glucose regulation .
16-1	2449-2451	It	abstract	giv	coref	19-30
16-2	2452-2454	is	_	_	_	_
16-3	2455-2459	well	_	_	_	_
16-4	2460-2465	known	_	_	_	_
16-5	2466-2470	that	_	_	_	_
16-6	2471-2479	incretin	abstract|substance[128]	new|new[128]	coref|coref	17-1[138_128]|17-1[138_128]
16-7	2480-2488	hormones	substance[128]	new[128]	_	_
16-8	2489-2502	glucagon-like	substance[128]	new[128]	_	_
16-9	2503-2510	peptide	object	giv	_	_
16-10	2511-2512	1	_	_	_	_
16-11	2513-2514	(	_	_	_	_
16-12	2515-2520	GLP-1	time	new	_	_
16-13	2521-2522	)	_	_	_	_
16-14	2523-2526	and	_	_	_	_
16-15	2527-2544	glucose-dependent	abstract[132]	new[132]	appos	16-19[0_132]
16-16	2545-2559	insulinotropic	abstract|abstract[132]	new|new[132]	_	_
16-17	2560-2571	polypeptide	abstract[132]	new[132]	_	_
16-18	2572-2573	(	_	_	_	_
16-19	2574-2577	GIP	abstract	giv	_	_
16-20	2578-2579	)	_	_	_	_
16-21	2580-2583	are	_	_	_	_
16-22	2584-2595	responsible	_	_	_	_
16-23	2596-2599	for	_	_	_	_
16-24	2600-2607	insulin	abstract|event[135]	new|new[135]	_	_
16-25	2608-2615	release	event[135]	new[135]	_	_
16-26	2616-2619	and	_	_	_	_
16-27	2620-2627	glucose	substance|abstract[137]	giv|new[137]	_	_
16-28	2628-2638	regulation	abstract[137]	new[137]	_	_
16-29	2639-2640	.	_	_	_	_

#Text=These hormones are inactivated by a serine protease human dipeptidyl peptidase-4 ( DPP4 ) .
17-1	2641-2646	These	substance[138]	giv[138]	_	_
17-2	2647-2655	hormones	substance[138]	giv[138]	_	_
17-3	2656-2659	are	_	_	_	_
17-4	2660-2671	inactivated	_	_	_	_
17-5	2672-2674	by	_	_	_	_
17-6	2675-2676	a	substance[141]	giv[141]	coref	18-60[0_141]
17-7	2677-2683	serine	animal|substance[141]	giv|giv[141]	coref	18-59
17-8	2684-2692	protease	substance[141]	giv[141]	_	_
17-9	2693-2698	human	substance[141]	giv[141]	_	_
17-10	2699-2709	dipeptidyl	abstract|substance[141]	giv|giv[141]	_	_
17-11	2710-2721	peptidase-4	substance[141]	giv[141]	_	_
17-12	2722-2723	(	_	_	_	_
17-13	2724-2728	DPP4	object	giv	coref	18-59[160_0]
17-14	2729-2730	)	_	_	_	_
17-15	2731-2732	.	_	_	_	_

#Text=Since natural cyclic peptides are proven to inhibit various proteases , and to consider the beneficial aspects of cyclic peptides in comparison to small chemicals , like less toxicity , no accumulation in organs , and rapid degradation of peptides , we hypothesized that cyclic peptides from natural sources could be an alternative source of therapeutics to inhibit serine protease DPP4 for treatment of diabetes mellitus .
18-1	2733-2738	Since	_	_	_	_
18-2	2739-2746	natural	abstract[143]	giv[143]	coref	18-19[146_143]
18-3	2747-2753	cyclic	abstract[143]	giv[143]	_	_
18-4	2754-2762	peptides	abstract[143]	giv[143]	_	_
18-5	2763-2766	are	_	_	_	_
18-6	2767-2773	proven	_	_	_	_
18-7	2774-2776	to	_	_	_	_
18-8	2777-2784	inhibit	_	_	_	_
18-9	2785-2792	various	substance[144]	giv[144]	_	_
18-10	2793-2802	proteases	substance[144]	giv[144]	_	_
18-11	2803-2804	,	_	_	_	_
18-12	2805-2808	and	_	_	_	_
18-13	2809-2811	to	_	_	_	_
18-14	2812-2820	consider	_	_	_	_
18-15	2821-2824	the	abstract[145]	new[145]	_	_
18-16	2825-2835	beneficial	abstract[145]	new[145]	_	_
18-17	2836-2843	aspects	abstract[145]	new[145]	_	_
18-18	2844-2846	of	abstract[145]	new[145]	_	_
18-19	2847-2853	cyclic	abstract[145]|abstract[146]	new[145]|giv[146]	coref	18-45[154_146]
18-20	2854-2862	peptides	abstract[145]|abstract[146]	new[145]|giv[146]	_	_
18-21	2863-2865	in	abstract[145]|abstract[146]	new[145]|giv[146]	_	_
18-22	2866-2876	comparison	abstract[145]|abstract[146]|abstract[147]	new[145]|giv[146]|new[147]	_	_
18-23	2877-2879	to	abstract[145]|abstract[146]|abstract[147]	new[145]|giv[146]|new[147]	_	_
18-24	2880-2885	small	abstract[145]|abstract[146]|abstract[147]|substance[148]	new[145]|giv[146]|new[147]|giv[148]	_	_
18-25	2886-2895	chemicals	abstract[145]|abstract[146]|abstract[147]|substance[148]	new[145]|giv[146]|new[147]|giv[148]	_	_
18-26	2896-2897	,	abstract[145]|abstract[146]|abstract[147]|substance[148]	new[145]|giv[146]|new[147]|giv[148]	_	_
18-27	2898-2902	like	abstract[145]|abstract[146]|abstract[147]|substance[148]	new[145]|giv[146]|new[147]|giv[148]	_	_
18-28	2903-2907	less	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[149]	new[145]|giv[146]|new[147]|giv[148]|giv[149]	_	_
18-29	2908-2916	toxicity	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[149]	new[145]|giv[146]|new[147]|giv[148]|giv[149]	_	_
18-30	2917-2918	,	abstract[145]|abstract[146]|abstract[147]|substance[148]	new[145]|giv[146]|new[147]|giv[148]	_	_
18-31	2919-2921	no	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[150]	new[145]|giv[146]|new[147]|giv[148]|new[150]	_	_
18-32	2922-2934	accumulation	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[150]	new[145]|giv[146]|new[147]|giv[148]|new[150]	_	_
18-33	2935-2937	in	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[150]	new[145]|giv[146]|new[147]|giv[148]|new[150]	_	_
18-34	2938-2944	organs	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[150]|object	new[145]|giv[146]|new[147]|giv[148]|new[150]|new	_	_
18-35	2945-2946	,	abstract[145]|abstract[146]|abstract[147]|substance[148]	new[145]|giv[146]|new[147]|giv[148]	_	_
18-36	2947-2950	and	abstract[145]|abstract[146]|abstract[147]|substance[148]	new[145]|giv[146]|new[147]|giv[148]	_	_
18-37	2951-2956	rapid	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[152]	new[145]|giv[146]|new[147]|giv[148]|new[152]	_	_
18-38	2957-2968	degradation	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[152]	new[145]|giv[146]|new[147]|giv[148]|new[152]	_	_
18-39	2969-2971	of	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[152]	new[145]|giv[146]|new[147]|giv[148]|new[152]	_	_
18-40	2972-2980	peptides	abstract[145]|abstract[146]|abstract[147]|substance[148]|abstract[152]	new[145]|giv[146]|new[147]|giv[148]|new[152]	_	_
18-41	2981-2982	,	_	_	_	_
18-42	2983-2985	we	person	acc	ana	19-21
18-43	2986-2998	hypothesized	_	_	_	_
18-44	2999-3003	that	_	_	_	_
18-45	3004-3010	cyclic	abstract[154]	giv[154]	coref	18-52[156_154]
18-46	3011-3019	peptides	abstract[154]	giv[154]	_	_
18-47	3020-3024	from	abstract[154]	giv[154]	_	_
18-48	3025-3032	natural	abstract[154]|abstract[155]	giv[154]|new[155]	_	_
18-49	3033-3040	sources	abstract[154]|abstract[155]	giv[154]|new[155]	_	_
18-50	3041-3046	could	_	_	_	_
18-51	3047-3049	be	_	_	_	_
18-52	3050-3052	an	abstract[156]	giv[156]	coref	19-2[164_156]
18-53	3053-3064	alternative	abstract[156]	giv[156]	_	_
18-54	3065-3071	source	abstract[156]	giv[156]	_	_
18-55	3072-3074	of	abstract[156]	giv[156]	_	_
18-56	3075-3087	therapeutics	abstract[156]|abstract	giv[156]|giv	_	_
18-57	3088-3090	to	_	_	_	_
18-58	3091-3098	inhibit	_	_	_	_
18-59	3099-3105	serine	animal|object[160]	giv|giv[160]	coref|coref|coref|coref	19-28|19-36[0_160]|19-28|19-36[0_160]
18-60	3106-3114	protease	abstract|object[160]	giv|giv[160]	coref	19-29
18-61	3115-3119	DPP4	object[160]	giv[160]	_	_
18-62	3120-3123	for	_	_	_	_
18-63	3124-3133	treatment	abstract[161]	new[161]	_	_
18-64	3134-3136	of	abstract[161]	new[161]	_	_
18-65	3137-3145	diabetes	abstract[161]|abstract|abstract[163]	new[161]|giv|giv[163]	_	_
18-66	3146-3154	mellitus	abstract[161]|abstract[163]	new[161]|giv[163]	_	_
18-67	3155-3156	.	_	_	_	_

#Text=Among various naturally occurring cyclic peptides , oxytocin ( natural cyclic peptide ) was chosen in this study to prove our hypothesis that , cyclic peptides possess serine protease inhibition activity , and specifically inhibit DPP4 .
19-1	3157-3162	Among	_	_	_	_
19-2	3163-3170	various	abstract[164]	giv[164]	coref	19-25[170_164]
19-3	3171-3180	naturally	abstract[164]	giv[164]	_	_
19-4	3181-3190	occurring	abstract[164]	giv[164]	_	_
19-5	3191-3197	cyclic	abstract[164]	giv[164]	_	_
19-6	3198-3206	peptides	abstract[164]	giv[164]	_	_
19-7	3207-3208	,	_	_	_	_
19-8	3209-3217	oxytocin	substance	new	appos	19-10[166_0]
19-9	3218-3219	(	_	_	_	_
19-10	3220-3227	natural	substance[166]	giv[166]	coref	20-24[185_166]
19-11	3228-3234	cyclic	substance[166]	giv[166]	_	_
19-12	3235-3242	peptide	substance[166]	giv[166]	_	_
19-13	3243-3244	)	_	_	_	_
19-14	3245-3248	was	_	_	_	_
19-15	3249-3255	chosen	_	_	_	_
19-16	3256-3258	in	_	_	_	_
19-17	3259-3263	this	event[167]	new[167]	_	_
19-18	3264-3269	study	event[167]	new[167]	_	_
19-19	3270-3272	to	_	_	_	_
19-20	3273-3278	prove	_	_	_	_
19-21	3279-3282	our	person|abstract[169]	giv|new[169]	ana|coref|ana|coref	20-3|20-3[177_169]|20-3|20-3[177_169]
19-22	3283-3293	hypothesis	abstract[169]	new[169]	_	_
19-23	3294-3298	that	_	_	_	_
19-24	3299-3300	,	_	_	_	_
19-25	3301-3307	cyclic	abstract[170]	giv[170]	_	_
19-26	3308-3316	peptides	abstract[170]	giv[170]	_	_
19-27	3317-3324	possess	_	_	_	_
19-28	3325-3331	serine	animal|abstract[174]	giv|new[174]	coref|coref	20-6[0_174]|20-6[0_174]
19-29	3332-3340	protease	abstract|abstract[174]	giv|new[174]	_	_
19-30	3341-3351	inhibition	abstract|abstract[174]	giv|new[174]	coref	20-27[187_0]
19-31	3352-3360	activity	abstract[174]	new[174]	_	_
19-32	3361-3362	,	_	_	_	_
19-33	3363-3366	and	_	_	_	_
19-34	3367-3379	specifically	_	_	_	_
19-35	3380-3387	inhibit	_	_	_	_
19-36	3388-3392	DPP4	abstract	giv	coref	20-12
19-37	3393-3394	.	_	_	_	_

#Text=To demonstrate our hypothesis , activity atlas and field-based models of DPP4 inhibitors from natural origin were utilized to elucidate molecular insights of oxytocin peptide into DPP4 inhibition .
20-1	3395-3397	To	_	_	_	_
20-2	3398-3409	demonstrate	_	_	_	_
20-3	3410-3413	our	person|abstract[177]	giv|giv[177]	_	_
20-4	3414-3424	hypothesis	abstract[177]	giv[177]	_	_
20-5	3425-3426	,	_	_	_	_
20-6	3427-3435	activity	abstract|abstract[179]	giv|new[179]	coref|coref	21-19[192_0]|21-19[192_0]
20-7	3436-3441	atlas	abstract[179]	new[179]	_	_
20-8	3442-3445	and	_	_	_	_
20-9	3446-3457	field-based	abstract[180]	new[180]	_	_
20-10	3458-3464	models	abstract[180]	new[180]	_	_
20-11	3465-3467	of	abstract[180]	new[180]	_	_
20-12	3468-3472	DPP4	abstract[180]|abstract|abstract[182]	new[180]|giv|giv[182]	coref|coref	20-27|20-27
20-13	3473-3483	inhibitors	abstract[180]|abstract[182]	new[180]|giv[182]	_	_
20-14	3484-3488	from	abstract[180]|abstract[182]	new[180]|giv[182]	_	_
20-15	3489-3496	natural	abstract[180]|abstract[182]|abstract[183]	new[180]|giv[182]|new[183]	_	_
20-16	3497-3503	origin	abstract[180]|abstract[182]|abstract[183]	new[180]|giv[182]|new[183]	_	_
20-17	3504-3508	were	_	_	_	_
20-18	3509-3517	utilized	_	_	_	_
20-19	3518-3520	to	_	_	_	_
20-20	3521-3530	elucidate	_	_	_	_
20-21	3531-3540	molecular	abstract[184]	new[184]	coref	22-27[204_184]
20-22	3541-3549	insights	abstract[184]	new[184]	_	_
20-23	3550-3552	of	abstract[184]	new[184]	_	_
20-24	3553-3561	oxytocin	abstract[184]|object[185]	new[184]|giv[185]	coref	22-13[0_185]
20-25	3562-3569	peptide	abstract[184]|object[185]	new[184]|giv[185]	_	_
20-26	3570-3574	into	_	_	_	_
20-27	3575-3579	DPP4	abstract|abstract[187]	giv|giv[187]	coref|coref	22-37|22-37
20-28	3580-3590	inhibition	abstract[187]	giv[187]	_	_
20-29	3591-3592	.	_	_	_	_

#Text=In addition , molecular docking simulations were used to understand the binding poses and interacting residues responsible for inhibitory activity .
21-1	3593-3595	In	_	_	_	_
21-2	3596-3604	addition	_	_	_	_
21-3	3605-3606	,	_	_	_	_
21-4	3607-3616	molecular	event[189]	giv[189]	_	_
21-5	3617-3624	docking	place|event[189]	giv|giv[189]	_	_
21-6	3625-3636	simulations	event[189]	giv[189]	_	_
21-7	3637-3641	were	_	_	_	_
21-8	3642-3646	used	_	_	_	_
21-9	3647-3649	to	_	_	_	_
21-10	3650-3660	understand	_	_	_	_
21-11	3661-3664	the	abstract[190]	new[190]	_	_
21-12	3665-3672	binding	abstract[190]	new[190]	_	_
21-13	3673-3678	poses	abstract[190]	new[190]	_	_
21-14	3679-3682	and	_	_	_	_
21-15	3683-3694	interacting	abstract[191]	new[191]	_	_
21-16	3695-3703	residues	abstract[191]	new[191]	_	_
21-17	3704-3715	responsible	abstract[191]	new[191]	_	_
21-18	3716-3719	for	_	_	_	_
21-19	3720-3730	inhibitory	abstract[192]	giv[192]	_	_
21-20	3731-3739	activity	abstract[192]	giv[192]	_	_
21-21	3740-3741	.	_	_	_	_

#Text=Also , the stability of water molecules at the binding site of oxytocin was studied using 3D reference interaction site model ( 3D-RISM ) to gain deep insights into the binding of the cyclic peptide at DPP4 druggable region .
22-1	3742-3746	Also	_	_	_	_
22-2	3747-3748	,	_	_	_	_
22-3	3749-3752	the	abstract[193]	new[193]	_	_
22-4	3753-3762	stability	abstract[193]	new[193]	_	_
22-5	3763-3765	of	abstract[193]	new[193]	_	_
22-6	3766-3771	water	abstract[193]|substance|substance[195]	new[193]|new|new[195]	_	_
22-7	3772-3781	molecules	abstract[193]|substance[195]	new[193]|new[195]	_	_
22-8	3782-3784	at	abstract[193]|substance[195]	new[193]|new[195]	_	_
22-9	3785-3788	the	abstract[193]|substance[195]|object[197]	new[193]|new[195]|new[197]	coref	22-20[0_197]
22-10	3789-3796	binding	abstract[193]|substance[195]|object|object[197]	new[193]|new[195]|giv|new[197]	coref	22-30[205_0]
22-11	3797-3801	site	abstract[193]|substance[195]|object[197]	new[193]|new[195]|new[197]	_	_
22-12	3802-3804	of	abstract[193]|substance[195]|object[197]	new[193]|new[195]|new[197]	_	_
22-13	3805-3813	oxytocin	abstract[193]|substance[195]|object[197]|substance	new[193]|new[195]|new[197]|giv	coref	22-33[206_0]
22-14	3814-3817	was	_	_	_	_
22-15	3818-3825	studied	_	_	_	_
22-16	3826-3831	using	_	_	_	_
22-17	3832-3834	3D	abstract[202]	new[202]	appos	22-23[0_202]
22-18	3835-3844	reference	person|abstract[202]	new|new[202]	_	_
22-19	3845-3856	interaction	abstract|abstract[202]	new|new[202]	_	_
22-20	3857-3861	site	object|abstract[202]	giv|new[202]	_	_
22-21	3862-3867	model	abstract[202]	new[202]	_	_
22-22	3868-3869	(	_	_	_	_
22-23	3870-3877	3D-RISM	abstract	giv	_	_
22-24	3878-3879	)	_	_	_	_
22-25	3880-3882	to	_	_	_	_
22-26	3883-3887	gain	_	_	_	_
22-27	3888-3892	deep	abstract[204]	giv[204]	_	_
22-28	3893-3901	insights	abstract[204]	giv[204]	_	_
22-29	3902-3906	into	abstract[204]	giv[204]	_	_
22-30	3907-3910	the	abstract[204]|object[205]	giv[204]|giv[205]	_	_
22-31	3911-3918	binding	abstract[204]|object[205]	giv[204]|giv[205]	_	_
22-32	3919-3921	of	abstract[204]|object[205]	giv[204]|giv[205]	_	_
22-33	3922-3925	the	abstract[204]|object[205]|object[206]	giv[204]|giv[205]|giv[206]	coref	23-13[212_206]
22-34	3926-3932	cyclic	abstract[204]|object[205]|object[206]	giv[204]|giv[205]|giv[206]	_	_
22-35	3933-3940	peptide	abstract[204]|object[205]|object[206]	giv[204]|giv[205]|giv[206]	_	_
22-36	3941-3943	at	abstract[204]|object[205]|object[206]	giv[204]|giv[205]|giv[206]	_	_
22-37	3944-3948	DPP4	abstract[204]|object[205]|object[206]|place|place[208]	giv[204]|giv[205]|giv[206]|giv|new[208]	_	_
22-38	3949-3958	druggable	abstract[204]|object[205]|object[206]|place[208]	giv[204]|giv[205]|giv[206]|new[208]	_	_
22-39	3959-3965	region	abstract[204]|object[205]|object[206]|place[208]	giv[204]|giv[205]|giv[206]|new[208]	_	_
22-40	3966-3967	.	_	_	_	_

#Text=Finally , fluorescence assay was used to demonstrate the potential role of oxytocin as a DPP4 inhibitor experimentally .
23-1	3968-3975	Finally	_	_	_	_
23-2	3976-3977	,	_	_	_	_
23-3	3978-3990	fluorescence	abstract|abstract[210]	new|new[210]	_	_
23-4	3991-3996	assay	abstract[210]	new[210]	_	_
23-5	3997-4000	was	_	_	_	_
23-6	4001-4005	used	_	_	_	_
23-7	4006-4008	to	_	_	_	_
23-8	4009-4020	demonstrate	_	_	_	_
23-9	4021-4024	the	abstract[211]	new[211]	_	_
23-10	4025-4034	potential	abstract[211]	new[211]	_	_
23-11	4035-4039	role	abstract[211]	new[211]	_	_
23-12	4040-4042	of	abstract[211]	new[211]	_	_
23-13	4043-4051	oxytocin	abstract[211]|substance[212]	new[211]|giv[212]	_	_
23-14	4052-4054	as	abstract[211]|substance[212]	new[211]|giv[212]	_	_
23-15	4055-4056	a	abstract[211]|substance[212]	new[211]|giv[212]	_	_
23-16	4057-4061	DPP4	abstract[211]|substance[212]	new[211]|giv[212]	_	_
23-17	4062-4071	inhibitor	abstract[211]|substance[212]	new[211]|giv[212]	_	_
23-18	4072-4086	experimentally	abstract[211]|substance[212]	new[211]|giv[212]	_	_
23-19	4087-4088	.	_	_	_	_
